SCHEMBL24258029

SCHEMBL24258029

Nc1ccc(-c2noc(Cc3ccc(Cl)c(Cl)c3)n2)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC1 P07992 1/20 0.50
ERCC4 Q92889 1/20 0.50
TSHR P16473 6/20 0.49
MAPK1 P28482 5/20 0.49
TDP1 Q9NUW8 5/20 0.49
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
GAA P10253 1/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C9 P11712 1/20 0.47
CYP2C19 P33261 1/20 0.47
KMT2A Q03164 5/20 0.46
L3MBTL1 Q9Y468 4/20 0.46
MEN1 O00255 3/20 0.46
LMNA P02545 2/20 0.46
SMN1; SMN2 Q16637 5/20 0.44
ALOX15 P16050 1/20 0.44
RAB9A P51151 3/20 0.44
ALDH1A1 P00352 2/20 0.42
NOTUM Q6P988 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24258075 0.88 ERCC1 (0.52) ERCC1ERCC4TSHRMAPK1TDP1
SCHEMBL26004923 0.85 L3MBTL1 (0.50) ERCC1ERCC4TSHRMAPK1TDP1
SCHEMBL24258080 0.85 ERCC1 (0.56) ERCC1ERCC4TSHRMAPK1TDP1
SCHEMBL26006195 0.83 L3MBTL1 (0.47) ERCC1ERCC4TSHRMAPK1TDP1
SCHEMBL24258035 0.82 ERCC1 (0.47) ERCC1ERCC4TSHRMAPK1TDP1
SCHEMBL24258089 0.80 ERCC1 (0.45) ERCC1ERCC4TSHRMAPK1TDP1
SCHEMBL26004943 0.79 MAPK1 (0.67) ERCC1ERCC4TSHRMAPK1TDP1
SCHEMBL24258087 0.78 S1PR1 (0.63) ERCC1ERCC4TSHRMAPK1TDP1
SCHEMBL24258081 0.77 ERCC1 (0.45) ERCC1ERCC4TSHRMAPK1TDP1
SCHEMBL26004989 0.77 ERCC1 (0.44) ERCC1ERCC4TSHRMAPK1TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. 2023-08-24 US disclosed
WO-2022035805-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230265082-A1 SUBSTITUTED 1,2,4-OXADIAZOLES AS SMALL MOLECULE INHIBITORS OF UBIQUITIN-SPECIFIC PROTEASE 28 USP28, USP1, USP18 ERCC1 2832/4885ERCC4 1843/4885TSHR 4539/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.